We are live on ! Find out more
DGX icon

Quest Diagnostics

242.76 USD
-1.85
0.76%
At close Updated Aug 28, 4:00 PM EDT
Pre-market
After hours
242.76
0.00
0%
1 day
-0.76%
5 days
-0.5%
1 month
2.89%
3 months
23.73%
6 months
15.46%
Year to date
39.69%
1 year
35.47%
5 years
61.01%
10 years
187.87%
 

About: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Employees: 57,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 61.7%
Neutral 36.2%
Negative 2.1%
Neutral
PRNewsWire
4 days ago
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m.
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
Neutral
PRNewsWire
4 days ago
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platform LONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform. Individuals now have the option to select the Humanity Biological Age add-on when purchasing select health profile tests from questhealth.com including Elite Health Profile, Men's and Women's Comprehensive Health Profiles, and Fitness Profile — Elite, with no additional blood draw needed.
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
Neutral
PRNewsWire
5 days ago
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Monday, September 14, 2026, at 10:00 a.m.
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
Neutral
PRNewsWire
5 days ago
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10% indeterminate rate, so more patients can receive an actionable insight SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Negative
Zacks Investment Research
7 days ago
Is it the Right Time to Retain DGX Stock in Your Portfolio?
Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
Is it the Right Time to Retain DGX Stock in Your Portfolio?
Positive
Zacks Investment Research
8 days ago
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Positive
Zacks Investment Research
10 days ago
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why
Neutral
Business Wire
11 days ago
WHOOP Makes Advanced Labs Available Without a Wearable Membership
BOSTON--(BUSINESS WIRE)--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX). WHOOP Advanced Labs combines comprehensive blood testing, clinician-reviewed results, AI-powered insights, and personalized recommendations to give people a d.
WHOOP Makes Advanced Labs Available Without a Wearable Membership
Positive
Zacks Investment Research
12 days ago
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Positive
Zacks Investment Research
14 days ago
Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know
Price charts implemented using Lightweight Charts™